Targazyme, Inc, based in Carlsbad, CA, is a pioneering biopharmaceutical company dedicated to developing next-generation immunotherapies for late-stage liquid and solid cancers. Their innovative proprietary cell efficacy multiplier technology enables precise delivery of immune cells to disease sites, amplifying the power of the patient's immune system to effectively eliminate, cure, and even prevent cancer, potentially redefining the landscape of cancer treatment.
With an impressive portfolio of 27 worldwide patents, 10 patents pending, and 40 strategic collaborations, Targazyme aims to establish itself as the undisputed market leader in the field of cancer immunotherapy. Their mission is to transform the survival and quality of life for late-stage cancer patients worldwide by providing best-in-class immunotherapies that facilitate cancer cures without the life-threatening side effects commonly associated with current standard-of-care therapies.
Generated from the website